Last reviewed · How we verify
AZD8205 in combination with AZD9574 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD8205 in combination with AZD9574 (AZD8205 in combination with AZD9574) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD8205 in combination with AZD9574 TARGET | AZD8205 in combination with AZD9574 | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD8205 in combination with AZD9574 CI watch — RSS
- AZD8205 in combination with AZD9574 CI watch — Atom
- AZD8205 in combination with AZD9574 CI watch — JSON
- AZD8205 in combination with AZD9574 alone — RSS
Cite this brief
Drug Landscape (2026). AZD8205 in combination with AZD9574 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd8205-in-combination-with-azd9574. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab